Artificial cell therapy: New strategies for the therapeutic delivery of live bacteria

被引:55
作者
Prakash, S
Jones, ML
机构
[1] McGill Univ, Biomed Technol & Cell Therapy Res Lab, Dept Biomed Engn, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Fac Med, Artificial Cells & Organs Res Ctr, Montreal, PQ H3A 2B4, Canada
来源
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY | 2005年 / 01期
关键词
D O I
10.1155/JBB.2005.44
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
There has been rapid growth in research regarding the use of live bacterial cells for therapeutic purposes. The recognition that these cells can be genetically engineered to synthesize products that have therapeutic potential has generated considerable interest and excitement among clinicians and health professionals. It is expected that a wide range of disease modifying substrates such as enzymes, hormones, antibodies, vaccines, and other genetic products will be used successfully and will impact upon health care substantially. However, a major limitation in the use of these bacterial cells is the complexity of delivering them to the correct target tissues. Oral delivery of live cells, lyophilized cells, and immobilized cells has been attempted but with limited success. Primarily, this is because bacterial cells are incapable of surviving passage through the gastrointestinal tract. In many occasions, when given orally, these cells have been found to provoke immunogenic responses that are undesirable. Recent studies show that these problems can be overcome by delivering live bacterial cells, such as genetically engineered cells, using artificial cell microcapsules. This review summarizes recent advances in the therapeutic use of live bacterial cells for therapy, discusses the principles of using artificial cells for the oral delivery of bacterial cells, outlines methods for preparing suitable artificial cells for this purpose, addresses potentials and limitations for their application in therapy, and provides insight for the future direction of this emergent and highly prospective technology.
引用
收藏
页码:44 / 56
页数:13
相关论文
共 112 条
[1]  
Akiyama K., 1994, ACTA NEONATOLOGICA J, V30, P130
[2]   Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans [J].
Anderson, JW ;
Gilliland, SE .
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 1999, 18 (01) :43-50
[3]   Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019) [J].
Arunachalam, K ;
Gill, HS ;
Chandra, RK .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2000, 54 (03) :263-267
[4]   Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections:: A randomized study [J].
Arvola, T ;
Laiho, K ;
Torkkeli, S ;
Mykkänen, H ;
Salminen, S ;
Maunula, L ;
Isolauri, E .
PEDIATRICS, 1999, 104 (05) :art. no.-e64
[5]   EFFECT OF MEDIUM AND TEMPERATURE OF STORAGE ON VIABILITY OF LACTIC-ACID BACTERIA IMMOBILIZED IN KAPPA-CARRAGEENAN-LOCUST BEAN GUM GEL BEADS [J].
AUDET, P ;
PAQUIN, C ;
LACROIX, C .
BIOTECHNOLOGY TECHNIQUES, 1991, 5 (04) :307-312
[6]   IMMOBILIZED GROWING LACTIC-ACID BACTERIA WITH K-CARRAGEENAN - LOCUST BEAN GUM GEL [J].
AUDET, P ;
PAQUIN, C ;
LACROIX, C .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 1988, 29 (01) :11-18
[7]   BATCH FERMENTATIONS WITH A MIXED CULTURE OF LACTIC-ACID BACTERIA IMMOBILIZED SEPARATELY IN KAPPA-CARRAGEENAN LOCUST BEAN GUM GEL BEADS [J].
AUDET, P ;
PAQUIN, C ;
LACROIX, C .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 1990, 32 (06) :662-668
[8]  
Awrey DE, 1996, BIOTECHNOL BIOENG, V52, P472, DOI 10.1002/(SICI)1097-0290(19961120)52:4<472::AID-BIT3>3.0.CO
[9]  
2-M
[10]  
BAICHWAL AR, 1997, Patent No. 5670168